DDInter76 DDInter899
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Amiodarone {u} (Compound) resembles {v} (Compound) Dronedarone
Amiodarone {u} (Compound) resembles {v} (Compound) Lucanthone
Amiodarone {u} (Compound) binds {v} (Gene) CACNA2D2
Amiodarone {u} (Compound) upregulates {v} (Gene) HMGCS1
Amiodarone {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Amiodarone {u} (Compound) downregulates {v} (Gene) PRPF4
Amiodarone {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Amiodarone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Liothyronine
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Amiodarone (Compound) resembles Dronedarone (Compound)
Amiodarone (Compound) resembles Lucanthone (Compound)
Amiodarone (Compound) binds CACNA2D2 (Gene)
Amiodarone (Compound) upregulates HMGCS1 (Gene)
Amiodarone (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Amiodarone (Compound) downregulates PRPF4 (Gene)
Amiodarone (Compound) causes Dermatitis exfoliative (Side Effect)
Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib